Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncopeptides AB

www.oncopeptides.se

Latest From Oncopeptides AB

Accelerated Approval Submission On The HORIZON For Oncopeptides’ Melflufen

US FDA says Phase II HORIZON data in relapsed triple-class refractory multiple myeloma can support NDA; Oncopeptides aims for submission Q1 2020.

Review Pathway Cancer

Myeloma Milestones: Selinexor May Be Next Novel Agent While Established Drugs Expand Indications

Karyopharm's selinexor could be the next novel drug approved for multiple myeloma, which has seen a deluge of new treatment regimens. With room for improvement, the pipeline is full of milestones for approved and new therapies.

Launches Life Cycle Management

Multiple Myeloma: Pricing And Reimbursement Challenges Escalate Even As Blockbusters Go Generic

As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.

Market Access Pricing Strategies

Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.

Business Strategies Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Oncopeptides AB
  • Senior Management
  • Jakob Lindberg, CEO
    Eva Nordstrom, Head, Clinical
    Klaas Bakker, CMO
  • Contact Info
  • Oncopeptides AB
    Phone: 705 695 471
    Vastra Tragardsgatan 15
    Stockholm, 111 53
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register